Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Marjan Gharagozloo, Isfahan University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT01752153
First received: November 21, 2012
Last updated: December 18, 2012
Last verified: November 2012
  Purpose

A wide spectrum of immune abnormalities has been described by numerous studies involving β-thalassemic patients with multiple transfusions. The abnormalities observed are both quantitative and functional, and concern several components of the immune response. Flavonoids are phenolic compounds widely distributed in plants, which were reported to exert multiple biological effects, including antioxidant and free radical scavenging abilities. Silymarin, a flavonolignan complex isolated from milk thistle (Silybum marianum L. Gaertn), have been classified as cytoprotective, antioxidant, anti-inflammatory, and especially as hepatoprotective agents. Silymarin is already being used clinically for treatment of liver diseases.It is considered safe and well-tolerated, with reported adverse events similar to placebo. Several studies have also reported immunomodulatory actions of silymarin. It increases lymphocyte proliferation, interferon gamma, interleukin (IL)-4 and IL-10 secretions by stimulated lymphocytes in a dose-dependent manner. It has been shown that in vitro treatment of peripheral blood mononuclear cells with silymarin causes restoration of the thiol status and increases in T cell proliferation and activation. Because reactive oxygen species and iron overload play important roles in the pathophysiology of thalassemia, silymarin may be an effective therapy due to its antioxidant, immunomodulatory, cytoprotective and iron chelating activities. The present study designed to investigate the therapeutic activity of orally administered silymarin for treatment of β-thalassemia major, a well-known and prevalent disease in Iran, which is associated with oxidative stress, iron overload and immune abnormalities.


Condition Intervention Phase
Immune Abnormalities
Drug: Desferrioxamine, Legalon® (Silymarin)
Drug: Silymarin (Legalon)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Shiraz University of Medical Sciences:

Primary Outcome Measures:
  • Change from Baseline in T cell proliferation [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    PHA-activated T Cell Proliferation in Cell Culture was studied by Brdu Incorporation ELISA-based Assay

  • Changes from baseline the percentage of lymphocyte subsets [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The percentage of T cell, B cell, and NK cells were studied using flowcytometry

  • Changes from baseline the production of cytokines in activated T cells [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The concentrations of IL-2, IL-4, and IFN-gamma in supernatant of activated T cells were measured using ELISA assay.


Enrollment: 25
Study Start Date: June 2012
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Silymarin (Legalon)
Patients who were unable or unwilling to use desferrioxamine or had stopped desferrioxamine treatment for at least 6 months, were received only silymarin.
Drug: Silymarin (Legalon)
Experimental: Combined therapy (Deaferrioxamine+Silymarin (Legalon)
In combined therapy group, patients continued desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy) was added to desferrioxamine regimen at the dose of 140 mg, taken orally, three times a day, 7 days a week.
Drug: Desferrioxamine, Legalon® (Silymarin)
Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Homozygous beta-thalassemia major
  • Regularly blood transfusion
  • Iron chelation therapy with subcutaneous desferrioxamine (DFO)40.0 mg/Kg/day for 5-7 days/week

Exclusion Criteria:

  • Chronic hepatitis B infection
  • Active hepatitis C infection
  • A history of a positive HIV test
  • Chronic renal or heart failure
  • Iron chelation therapy with deferiprone
  • Pregnancy
  • Gastrointestinal conditions preventing absorption of an oral medication o
  • noncompliance with prescribed therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01752153

Locations
Iran, Islamic Republic of
Department of Immunology, School of Medicine, Shiraz University of Medical Sciences
Shiraz, Fars, Iran, Islamic Republic of
Sponsors and Collaborators
Shiraz University of Medical Sciences
Investigators
Study Director: Zahra Amirghofran, PhD Shiraz University of Medical Sciences
  More Information

No publications provided

Responsible Party: Marjan Gharagozloo, Assistant professor, Isfahan University of Medical Sciences
ClinicalTrials.gov Identifier: NCT01752153     History of Changes
Other Study ID Numbers: 1929
Study First Received: November 21, 2012
Last Updated: December 18, 2012
Health Authority: Iran: Ethics Committee

Keywords provided by Shiraz University of Medical Sciences:
Focus
immunomodulatory effect
of silymarin
on cell mediated immunity
Beta-Thalassemia
major patients.

Additional relevant MeSH terms:
Beta-Thalassemia
Anemia
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Hematologic Diseases
Hemoglobinopathies
Thalassemia
Deferoxamine
Silymarin
Antioxidants
Chelating Agents
Iron Chelating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Sequestering Agents
Siderophores

ClinicalTrials.gov processed this record on October 29, 2014